Ceritinib is also a second-generation ALK TKI and is 20 times as potent as crizotinib against ALK-positive NSCLC, has significant antitumor activity against both crizotinib-sensitive and crizotinib-resistant tumors, and has better efficacy in the Asian population (16). Here, ALK is linked to non-small cell lung carcinoma.